Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dasatinib + RO7283420 + Tocilizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dasatinib | Sprycel | BMS-354825 | ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 32 BTK inhibitor 37 CSF1R Inhibitor 28 DDR1 Inhibitor 10 DDR2 inhibitor 7 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 SRC Inhibitor 31 TNK2 Inhibitor 6 | Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov). |
RO7283420 | RO-7283420|RO 7283420|RG6007|RG-6007|RG 6007|HLA-A2-WT1 x CD3 RG6007 | CD3 Antibody 99 | RO7283420 is a T-cell receptor-like T-cell engaging bispecific antibody (T-BsAb) that targets a 9-amino acid peptide derived from Wilms tumor 1 (WT1) and CD3 expressed on T-lymphocytes, which potentially leads to a cytotoxic T-lymphocyte response against tumor cells expressing WT1 (NCI Drug Dictionary). | |
Tocilizumab | Actemra | Atlizumab | Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04580121 | Phase I | Dasatinib + RO7283420 + Tocilizumab | A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. | Completed | USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 1 |